• Free Book
  • Store
    • Books
    • Free First Chapters
    • Free Newsletters
  • Recent Articles

TradingMarkets.com

Quantified Stock Market Trading Strategies & Systems

  • Home
  • New Trading Research
  • Education
    • Articles
      • Connors Research
      • ETFs
      • Options
      • Stocks
      • Volatility
    • Trading Lessons
    • Connors Research
    • Glossary
    • Interview Archive
    • Videos
  • Python
  • Quantamentals
    • Quantamentals: The Next Great Forefront of Trading and Investing
    • Quantamentals Resources
  • Courses
  • Store
    • New Book! The Alpha Formula
    • “Buy The Fear, Sell The Greed” – Best Seller!
    • Swing Trading College 2019
    • Trading Books and Guidebooks
    • Street Smarts
    • Online Trading Courses
    • Private Mentoring with Larry Connors
    • Customized Trading Research
    • Amibroker Strategy Add On Modules
You are here: Home / Recent / ETF of the Week: iShares Nasdaq Biotechnology Index Fund ETF

ETF of the Week: iShares Nasdaq Biotechnology Index Fund ETF

February 26, 2012 by David Penn

It took a move of more than 70% in shares of Vivus (NASDAQ: VVUS) to get the stock market

punditry to pay attention to some of the amazing, positive things going on in the biotechnology sector.

Fortunately, for those of us still focused on buying short-term weakness and selling short-

term strength, the attention spans of most of those in the financial media is such that we can

count on their forgetfulness to again provide oversold and overbought extremes in these and

other stocks in the market.

The most recent panic over the plunge in shares of Gilead Sciences (NASDAQ: GILD) likely blinded many traders and active investors to the potential opportunities for

pursuing sector-wide weakness on the long side. For example, the iShares Nasdaq Biotechnology Index Fund ETF (NASDAQ: IBB) pulled back for three consecutive days in mid-February, closing in technically oversold territory for each session as traders sold biotech en masse in the wake of negative news about Gilead’s hepatitis C drug. And this sell-off provided classic opportunities for short-term traders and active investors to take advantage of the over-reaction.

IBB chart

Traders who bought IBB as it earned “consider buying” ratings of 9 out of 10, and then

added to their position when the ETF closed lower – and earned a further upgrade to our

highest, 10 out of 10 level, were able to take long positions at some of the lowest levels of

the sell-off. Additionally, traders did not have to wait long to lock in gains. Just one day

after earning our highest, 10 out of 10 rating, the iShares Nasdaq Biotechnology Index Fund

ETF was up more than more than 2%, closing above its 5-day moving average and back in short-

term overbought territory.

Note that a similar pullback and major ratings upgrade took place in the S&P Biotech SPDRS

ETF (NYSE: XBI). One difference with XBI is that this fund earned a “consider buying” rating

of 8 out of 10, rather than a 9 out of 10 as with IBB, before earning the 10 out of 10 upgrade

on the correction low of February 22nd.

To learn more about trading exchange-traded funds using scale-in strategies like these,

click here.

And to start trading ETFs using PowerRatings, click the link below to start your free,

14-day, no obligation trial.

Scan Just One

Number Tonight … to Find Stocks on the Move Tomorrow

Filed Under: Recent, Trading Lessons, Trading Lessons Tagged With: ETF of the Week, PowerRatings

Buy The Fear, Sell The Greed

Buy The Fear, Sell The Greed

Swing Trading College

New Book From Larry Connors and Chris Cain, CMT – "The Alpha Formula; High Powered Strategies to Beat The Market With Less Risk"

We’re excited to announce the release of a new investment book written by Larry Connors and Chris Cain, CMT. The book, “The Alpha Formula; High Powered Strategies to Beat The Market With Less Risk “ combines… Hedge fund legend Ray Dalio’s brilliant insight into combining uncorrelated strategies… With new, minimally correlated, quantified, systematic strategies to trade… [Read More]

Buy The Alpha Formula Now

Connors Research Traders Journal (Volume 57): 7 Real-World Reasons Why Short Strategies Should Be Included In Your Portfolio

In our new book, The Alpha Formula – High Powered Strategies to Beat the Market with Less Risk, we show the benefits of including short-strategies in your portfolio. As a reminder, building portfolios should be based on First Principles – otherwise known as truths. These truths are: Markets Go Up Market Go Down Markets Go… [Read More]

Company Info

The Connors Group, Inc.
185 Hudson St., Suite 2500
Jersey City, NJ 07311
www.cg3.com

About Us

About
Careers
Contact Us
Link To Us

Company Resources

Help
Privacy Policy
Return Policy
Terms & Conditions

Properties

TradingMarkets
Connors Research

Connect with TradingMarkets

Contact

info@cg3.com
973-494-7311 ext. 628

Free Book

Short Term Trading Strategies That Work

© Copyright 2020 The Connors Group, Inc.

Copyright © 2023 · News Pro Theme on Genesis Framework · WordPress · Log in